Circle Pharma Welcomes New Leaders to Enhance Drug Discovery
Circle Pharma Welcomes New Leaders to Enhance Drug Discovery
Circle Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing innovative cell-permeable macrocycles, has announced significant additions to its leadership team. These appointments are crucial as the company moves forward with its promising oncology pipeline and is committed to leveraging its MXMO macrocycle platform. Recently, Marie Evangelista, Ph.D., was appointed as the Senior Vice President and Head of Cancer Biology. Additionally, Constantine Kreatsoulas, Ph.D., has been promoted to Senior Vice President and Head of Discovery Technology Sciences. This reshaping of the executive team is strategically aligned with Circle's determination to enhance its pipeline of therapies, including its leading candidate, CID-078, which is undergoing evaluation in a Phase 1 clinical trial for solid tumors.
Strengthening Drug Discovery and Scientific Leadership
According to David J. Earp, JD, Ph.D., Circle's president and CEO, these strategic hires enhance the company’s drug discovery capabilities and scientific leadership. Earp expressed enthusiasm about the trajectory of CID-078, Circle's first oral macrocyle currently in clinical trials, emphasizing the critical role that Marie and Constantine will play in leading their respective teams. Their experience will be vital as Circle Pharma continues to broaden its focus on innovative therapies.
Marie Evangelista’s Expertise in Cancer Biology
Dr. Evangelista brings a wealth of experience, with over 18 years dedicated to translational oncology and small molecule drug discovery. Her previous roles include a significant tenure at Genentech, where she led advancements in KRAS-targeting programs. With a Ph.D. in cell and molecular biology from Queen's University in Ontario, Canada, Dr. Evangelista is eager to contribute her expertise at Circle Pharma. She commented on the importance of her role during this crucial period in the company’s growth, highlighting her commitment to developing transformative therapies for patients.
Constantine Kreatsoulas and the Advancement of Macrocycle Technologies
Dr. Kreatsoulas joined Circle Pharma in 2021 and has already made notable contributions to the organization, particularly in the development of the MXMO platform. Prior to his appointment, he held leadership roles at major pharmaceutical companies like GlaxoSmithKline and Merck & Co., gaining vital experience in molecular design and machine learning. As he steps into his new role, he expresses excitement about the technological advancements in macrocycles that Circle is pursuing.
About Circle Pharma, Inc.
Circle Pharma, based in South San Francisco, is committed to advancing the discovery and development of intrinsically cell-permeable macrocycles, which can be administered through several routes, including orally. The company's proprietary MXMO™ platform employs advanced synthetic chemistry and structure-based drug design methodologies to create a new generation of macrocycle therapeutics. Circle Pharma's current focus is on cyclins—critical elements that regulate the cell cycle and have significant implications in cancer treatment. Their lead therapeutic candidate, CID-078, is in clinical trials and represents just a portion of their growing macrocycle therapeutic portfolio.
As Circle Pharma continues to innovate and expand its offerings, the leadership changes are poised to foster significant advancements in drug discovery and development efforts. This approach marks a promising step towards addressing unmet clinical needs and improving patient outcomes.
Frequently Asked Questions
What recent changes occurred in Circle Pharma's leadership?
Circle Pharma appointed Marie Evangelista as Senior Vice President and Head of Cancer Biology, and promoted Constantine Kreatsoulas to Senior Vice President and Head of Discovery Technology Sciences.
What is Circle Pharma focused on developing?
Circle Pharma is focused on developing cell-permeable macrocycles for oncology therapies, using its MXMO platform to create innovative treatments addressing unmet clinical needs.
What is CID-078?
CID-078 is Circle Pharma's leading macrocycle therapy currently undergoing a Phase 1 clinical trial targeting solid tumors.
What experience does Marie Evangelista bring to Circle Pharma?
Dr. Evangelista has over 18 years in translational oncology and drug discovery, including a significant background at Genentech, where she advanced KRAS-targeting programs.
How does Circle Pharma's MXMO platform work?
The MXMO platform combines structure-based drug design and advanced synthetic chemistry to create new macrocycle therapies aimed at challenging drug targets.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Understanding Your Rights After IREN Stock Losses: What to Do
- Boeing Faces Challenges as Stock Prices Decline Amid Strike
- Advent Convertible and Income Fund Updates October Distribution Dates
- Strategic Collaboration Enhances Beneficial Ownership Reporting
- FTSI Merger with 21st Century AEYE: A New Era in Fintech
- Inspirato Unveils Partnership with Tonal for Luxury Fitness
- Saga Communications Elevates Leadership with New Executive Roles
- Discover New Opportunities with the University of Phoenix Guide
- Significant Trends in Marijuana Stock Performance This Month
- Understanding the Positive Price Trends for GLDD Stocks
Recent Articles
- EyePoint Pharmaceuticals Announces Inducement Awards for New Team Members
- Data Vault Holdings, Inc. Showcases Innovation at NYSDS 2024
- Southwest Airlines Celebrates Ratification of Labor Contracts
- Unicycive Therapeutics Set to Share Updates at Investor Forum
- Innovative Cytokine Solution Revolutionizes CAR-T Therapy Production
- Social Media Sparks Theories Following Trump Incident
- Nuvalent Launches $350 Million Public Offering for Growth
- Market Movements: Gold Gains Amid Dollar Weakening
- Broadridge Launches Revolutionary Platform for Asset Servicing
- Celebrating 90 Years of Lupin Lodge: A Legacy in Naturism
- Find Therapeutics Secures $8.1 Million for FTX-101 Development
- Empowering College Students Through Safe Dating Initiatives
- Legal-Bay Expands Services to Assist California Lawsuit Plaintiffs
- Lingerfelt Celebrates Full Occupancy at Ashton Logistics Park
- Univation's Technology Choice Impacts IOCL's PE Production Plans
- Three Women at Quantix Honored with Supply Chain Awards
- Innovative Cancer Treatment Unveiled by PhytoHealth Corporation
- Exciting New Franchise Opportunity for Tint World in Wisconsin
- Gogo Business Aviation and Airshare Unite for Enhanced Connectivity
- WaverBed's Latest Innovation: The Transformative WaverMat
- Vizsla Silver Secures $65 Million Financing for Expansion
- Domino's Introduces 5-Cheese Mac & Cheese for Fall Enjoyment
- FANUC Corp Faces Mixed Review Amidst Market Reassessments
- Yelp Faces Headwinds from Competition Despite Recent Growth
- Mosaic Company Faces Production Challenges and Strategic Changes
- TriSalus Life Sciences Shows Promise with Cancer Treatment Tech
- Metcash Stock Sees Positive Growth Amid Industry Changes
- Truist Elevates Builders FirstSource Rating Amid Growth Prospects
- AutoZone: Strategies for Growth Amidst Market Challenges
- JPMorgan Ups Rating for Northern Star Resources: What's Next?
- Understanding Market Reactions Ahead of Fed Interest Rate Changes
- Investors React to Hemlo Explorers' Promising Project Update
- Identifying Bargains: Analyzing Overlooked Stocks Today
- Exploring Michael Saylor's Bitcoin Predictions and Strategy
- LIS Technologies Welcomes Keith Everly as Security Chief
- Market Anticipation Grows Ahead of Fed's Decision Next Week
- Advancements in Dermatologic Surgery: ASDS Hosts Innovative Course
- VEON's Commitment to Ukraine: Investment and Growth Insights
- Can-Fite Advances Pancreatic Cancer Treatment with New Study
- Battery-Operated Smoke Detectors to Surpass $5 Billion by 2034
- D.O.G.E Shines Bright: A New Era of Memecoins Emerges
- Crypto Plus: Empowering the Global Cryptocurrency Community
- Leadership Changes at Lantronix: Strategic Transition Ahead
- Revolutionary Mpox Vaccine Candidate By Tonix Gains Support
- Zentalis Pharmaceuticals Celebrates FDA Approval to Resume Azenosertib Trials
- Critical Metals Corp: Driving Innovation in Lithium Supply Chains
- Nayax and Adyen's Strategic Partnership Set to Transform EV Payments
- WisdomTree Issues Notice on ETP Securities Threshold Changes
- ANI Pharmaceuticals Moves Forward with Alimera Acquisition
- Reliance, Inc.'s New Credit Facility: Unleashing Growth Potential